A Medical Device Daily
The Victorian Department of Human Services (DHS; Melbourne, Australia) has selected Cerner (Kansas City, Missouri) as its state-wide clinical information systems provider for its hospitals and clinics.
The projected value of the contract was not disclosed.
Victorian Health Minister Bronwyn Pike, said that the selection of Cerner “will enable public hospitals and clinics in Victoria to be connected, creating a more unified and integrated care network for its citizens.“
The agreement is a part of DHS' HealthSMART program and will provide Cerner's Millennium solutions into hospitals across Victoria – a state with 5 million people, or about 25% of Australia's population.
HealthSMART aims to improve patient care and reduce the administrative burden on healthcare professionals with a standardized approach to information technology, offering clinicians fast access to test results, medical histories and medication records. Computerized order entry will enable physicians to enter orders directly into the system, while providing decision support through reminders, alerts and recommendations. Clinicians will be able to retrieve medical information for more personalized care.
Cerner reports having more than 5,100 Millennium solutions “live“ at more than 950 client facilities around the world, from independent physicians to nationwide healthcare organizations.
“The state of Victoria is taking a leadership role in the global drive to improve patient safety and reduce medical error, and we are proud to dedicate our resources to be a part of that effort,“ said Trace Devanny, Cerner president.
Cerner says it is focused on taking the paper chart out of healthcare, eliminating error, variance and waste in the care process, and reports more than 1,500 clients worldwide,
Tomtec introduces new 4D echo solution
Tomtec (Munich, Germany), a developer of 2D and 3D/4D ultrasound, has introduced 4D LV-Function, describing it as a tool for comprehensive left ventricular (LV) analysis using 3D echocardiographic datasets.
The software focuses on clinical parameters for analyzing LV function and quantifying dyssynchrony, providing analyses and values with reproducibility at the bedside. The software tracks the endocardial border of the ventricle in 3D, providing a model that representing the geometry of the ventricle and deriving stroke volume and ejection fraction from those measurements.
Using a 16-segment model, it also can perform regional volumetric analysis on subdivisions of the ventricle. This makes it straightforward to diagnose problems of both global and regional function of the ventricle. 4D LV-Function also can assess the timing of regional contraction, presenting a measure of the dyssynchrony of the ventricle for selecting patients that should respond well to cardiac resynchronization therapy.
AVMD completes rest of IMT purchase
Advanced Medical Institute (AVMD; Sydney, Australia) reported that it has acquired the remaining 7% of the issued and outstanding shares of Intelligent Medical Technologies , an indirect 93% owned subsidiary, in connection with a share exchange agreement. AVMD will acquire the IMT shares from Anatoly Fanshil and Avina Investment in exchange for 1.26 million shares of AVMD restricted common stock or 3.49% of the shares of issued and outstanding common stock of AVMD.
Dr. Jacov Vaisman, president, CEO and chairman of AVMD and director of IMT, said, IMT and its intellectual property assets are an important component to our business strategy over the next few years.“ He added: “As recently announced, IMT has recently received approval from the Queensland Institute to undertake human testing of its nebulizer device to be used to deliver medications used in the treatment of sexual dysfunction.“
He said the testing will be completed in the second half of 2006. “We are finalizing an application to include the nebulizer on the register of medical devices with the Therapeutic Goods Administration [the Australian FDA] and the European Medicines Agency and hope to begin commercialization of the device later this year.“
Advanced Medical Institute Inc., through its wholly owned subsidiary, Advanced Medical Institute Pty Limited, (AMI Australia) is a provider of treatment programs for erectile dysfunction and premature ejaculation. The company operates 21 treatment clinics and sales centers in Australia and New Zealand.
IMT develops products relating to an ultrasonic nebulizer device to be used in the treatment of sexual dysfunction.
Safety of Aethlon Hemopurifier validated
Aethlon Medical (San Diego), a developer of therapeutic devices for infectious disease, reported that a safety study of patients treated with the Aethlon Hemopurifier has been completed at the Apollo Hospital in Delhi, India. Aethlon said it will include data from the study in Pandemic Influenza and Class “A“ Biological Weapon regulatory filings to be submitted to the FDA.
The Hemopurifier is a broad-spectrum device-treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu and chronic infectious disease targets, including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV).
In the trial, Hemopurifier safety was demonstrated in all patients enrolled. All patients suffered from end-stage renal disease as well as Hepatitis-C (HCV) infection. A total of four patients met the conditions to be enrolled and were treated in the study. The average patient age exceeded 50 years, and as a result of their severe condition, spent greater than 50% of their waking hours in bed.
The treatment regimen required each patient to be treated six times with the Hemopurifier over a two-week period, each treatment lasting four hours. The treatment regimen mirrored the patient's normal kidney dialysis schedule, which allowed for the inclusion of the Hemopurifier without disrupting dialysis treatment. No “material“ adverse events had been observed in the study, Aethlon said.
In addition to demonstrating safety, an approximate 30% capture of circulating HCV during each examined four-hour treatment, according to the researchers.
Vijay Kher, MD, principal investigator of the safety study, said he will initiate human efficacy studies of the Hemopurifier as a treatment for chronic and acute viral conditions in India. Aethlon said it is working with Kher, advisors at Qualtran and government officials in India to determine the infectious disease target of the initial efficacy study.
Aethlon is developing the first medical device to treat infectious disease. It reports also having begun research on a second-generation Hemopurifier targeting the capture of growth factors inherent in the spread of Cancer.
Elekta reports new Aussi installations
Elekta (Stockholm, Sweden) a developer of radiation therapy for non-invasive treatment of brain disorders, reported two new Elekta Synergy orders from North Coast Area Health Service inNew South Wales, Australia.
These orders come after other recent orders from Austin Health Hospital (Heidelberg, Victoria) and Townsville Hospital , (Queensland), the company said. And together represent total order value of more than AUD10 million.
Elekta said that the 9th International Workshop on Electronic Portal Imaging in Melbourne, April 8-12, featured three presentations on IGRT on Elekta's Synergy system.
In March, Elekta said it also received orders for advanced digital linear accelerators from Austin Health Hospital (Heidelberg, Victoria), also equipped with IGRT technology and the MOSAIQ EMR system, and from Townsville Hospital (Queensland). These systems are already delivered.
Elekta has recently also installed IMPAC's electronic medical record system atRadiation Oncology Victoria (Melbourne), up and running in all four of its centers and installed at the soon-to-be-opened fifth center.
Test kits approved by Saudi Arabia
Medical Services International (Edmonton, Alberta) reported receiving regulatory approval of its VScan Dengue Fever test kit in Saudi Arabia.
It said that currently there is an outbreak of Dengue Fever in the Middle East and that it believes that Saudi Arabia approval of the kit should increase its sales from 400,000 to 750,000 units.
The VScan rapid test kit is a single use, disposable test for the screening of HIV 1&2, Hepatitis B&C, tuberculosis, Dengue Fever, West Nile, syphilis, malaria and prostate cancer.
The kits cannot be sold in Canada.